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70Endothelial hyperpermeability is involved in several critical illnesses, and its
regulatory mechanisms have been intensively investigated. It was recently re-
ported that the activation peptide of coagulation factor IX enhances cell matrix
and intercellular adhesion. The aim of this study was to investigate the role of
activation peptide of coagulation factor IX in intercellular adhesion of endothe-
lial cells and evaluate its effects on endothelial permeability. In the presence of
activation peptide, cells spread with lamellipodium-like broad protrusions multi-
directionally, increasing the area of adhesion to matrix by 16% within 30 mi-
nutes. In intercellular adhesion, treatment with activation peptide induced
overlapping of adjacent cell edges and remodeling of intercellular adhesion
sites, with colocalization of the adherens junction proteins VE-cadherin and b-
catenin and a marker protein of the lateral border recycling compartment, PE-
CAM. Activation peptide decreased gaps between cells by 66% in cultured
endothelial cells and suppressed increased endothelial cell monolayer perme-
ability induced by interleukin-1b in a dose-dependent manner. Treatment with
activation peptide decreased eNOS protein expression and altered its subcellu-
lar distribution, decreasing intracellular cGMP. An analogue of cGMP sup-
pressed the effects of activation peptide on cell spreading. In addition, the
effect of activation peptide on hyperpermeability was investigated in mice in-
jected with lipopolysaccharide. Intravenous injection of lipopolysaccharide
increased lung weight by 28%, and treatment with activation peptide signifi-
cantly suppressed the increase in lung weight to 5%. Our results indicate that
activation peptide of factor IX regulates endothelial intercellular adhesion
and thus could be used in the treatment of vascular hyperpermeability. (Trans-
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AT A GLANCE COMMENTARY
Mamiya A, et al.
Background
Sepsis with systemic inflammatory response syn-
drome is a life-threatening disease even in devel-
oped countries. Currently, there are not any
established therapeutic methods for the clinical
condition. The activation peptide of coagulation
factor IX has been considered as a blocking peptide
of its catalytic activity in coagulation.
Translational Significance
In this study, we show that the activation peptide
strengthens barrier function of endothelial cells
in vitro and in vivo. Lung edema in sepsis model
was suppressed by the peptide. This study suggests
that the activation peptide could be a potential ther-
apeutic agent for sepsis with systemic inflamma-
tory response syndrome.
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Vascular permeability is strictly regulated to recon-
cile 2 conflicting aims: selective molecular transport
and the barrier function between blood and tissues. Tis-
sues must receive nourishment and oxygen from the
blood and excrete waste products to the blood. Endothe-
lial cells play a major role in regulating vascular perme-
ability under the influence of numerous factors. There
are 2 routes of fluid extravasation: transcellular trans-
port, by which fluids pass through endothelial cells by
vesicular trafficking; and paracellular transport,
involving modulation of intercellular adhesion.1 Trans-
cellular transport occurs through caveolae, vesiculo-
vacuola organelles, and transcellular channels.2,3
Caveolae are ‘dents’ in the plasma membrane
containing caveolin-1 and are the sites of caveolin-
dependent endocytosis. Caveolin-1 is a protein impor-
tant in transcellular transport, and its expression can
be suppressed by targeting the caveolin-1 gene.4,5
Paracellular transport is regulated by barrier stability,
which is maintained by anchorage of adherens and
tight junctions to the actin cytoskeleton.6 Adherens
junctions are formed with calcium-dependent VE-cad-
herin protein. Paracellular transport is stimulated by a
number of humoral factors, including VEGF, histamine,
thrombin, and bradykinin, which induce phosphoryla-
tion of specific tyrosine residues (Y658 and Y731) of
VE-cadherin.7,8 Phosphorylation of VE-cadherin re-
sults in internalization of the protein and attenuation
of intercellular adhesion, increasing paracellular perme-ability. Intracellularly, VEGF, bradykinin, and prosta-
glandin E2 control endothelial permeability through
the production of nitric oxide (NO).9-13
Increased endothelial permeability has important im-
plications in the pathophysiology and prognosis of
many diseases. The permeability of the vascular endo-
thelium is one of the factors that determine the fluid bal-
ance in organs and tissues. Vascular permeability must
be precisely controlled for normal organ and tissue
function, particularly in the lungs. To maintain the effi-
ciency of gas exchange, the lungs constantly maintain
an optimal amount of fluid. Dysregulation of the fluid
balance in the lungs can result in hypoxia, which can
be life-threatening. In addition, immune reactions
arising in response to infection or allergies enhance
endothelial permeability. In these cases, humoral factors
such as interleukin (IL), bradykinin, and histamine and
pathogen-derived lipopolysaccharide (LPS) increase
vascular permeability.2,9,14,15 In addition, hypoxia
increases the expression of VEGF, which is a potent
endothelial permeability–enhancing factor. Moreover,
the tissue damage resulting from ischemia can trigger
an inflammatory reaction.16,17 Coagulation reactions
can also enhance endothelial permeability. In addition,
various factors involved in hemostasis have been
found to increase permeability, including thrombin
and platelet-activating factors. Thrombus-associated
angiopathy causes ischemia, thus increasing perme-
ability. The inter-related nature of infection, inflamma-
tion, coagulation, and ischemia in diseases such as
sepsis, disseminated intravascular coagulation (DIC),
and acute respiratory distress syndrome indicates that
numerous factors may increase endothelial permeability
in a cooperative manner.
The number of reports regarding factors that suppress
increases in permeability and maintain endothelial bar-
rier functions continues to increase because it is thought
that such factors would be effective in treating diseases
such as sepsis, DIC, and acute respiratory distress syn-
drome. Humoral factors, catecholamines, thrombomo-
dulin, activated protein C (APC), and prostaglandins
are known to enhance endothelial barrier functions.
For example, the injection of adrenalin is an effective
treatment for increased lung permeability.18 Thrombo-
modulin is reportedly effective in the treatment of
DIC due to its anticoagulation activity and involvement
in protection of the endothelial barrier.19,20 The results
of sepsis model studies suggest that APC and
sphingosine-1-phosphate (S1P) would be effective
treatments for barrier dysfunction.21,22
Coagulation factor IX (FIX) is an essential molecule
for normal coagulation. Mutations in FIX lead to hemo-
philia B, which results in abnormal bleeding. In the
coagulation process, FIX is cleaved at Arg192 and
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complex, releasing an activation peptide from FIX and
resulting in the activation of FIX.23 Kitano et al.24 re-
ported that activated FIX increases the rate of cell
migration, weakens adhesion to matrix, and weakens
intercellular adhesion. In contrast, native FIX and the
activation peptide suppress migration, increase adhe-
sion to matrix, and enhance intercellular adhesion.
Moreover, the activation peptide suppresses the effects
of activated FIX. Because diseases involving abnor-
mally high-endothelial permeability are related to coag-
ulation, it is thought that activated FIX could be
involved in increasing endothelial permeability. Our hy-
pothesis is that the activation peptide could be an effec-
tive treatment due to its involvement in maintaining
endothelial barrier functions. Therefore, in the present
study, we examined the effects of the FIX activation
peptide on endothelial permeability both in vitro and
in vivo.
EXPERIMENTAL PROCEDURES
Cells and cell culture. Squamous cell carcinoma–
derived A431 cells were grown in 64 medium (60%
Opti-MEN [Invitrogen, Carlsbad, Calif], 40% LHC-8
medium [Invitrogen]). Human umbilical vein
endothelial cells (HUVECs) were grown in Medium
200 (Invitrogen) with a Low-serum Growth
Supplement kit (Invitrogen).
Reagents. We generated several FIX deletion mutants
by RT-PCR and cloned them into an alkaline
phosphatase (AP)-tag4 vector (GenHunter, Nashville,
Tenn) for production of AP-tagged FIX as a secreted
protein in CHO cells cultured in 64 medium.25,26 The
DNA constructs included mouse full-length FIX
(amino acids 47-471; accession number AK149372)
without the amino-terminal propeptide, a fragment of
FIX lacking the heavy chain (amino acids 47-236), the
FIX light chain (amino acids 47-191), the activation
peptide (amino acids 193-236), and the first EGF
domain of FIX (amino acids 97-130). Chemically
synthesized peptides (FIX amino acids 193-216 and
193-210) and a control peptide were purchased from
Operon Technology (Tokyo, Japan). To optimize the
peptide synthesis conditions, poly K was added to
the C terminus of synthesized peptides as
AETVFSMDYENSTEAVFIQDDITKKKKKK. The
control peptide consisted of amino acids 193-216 in
reverse sequence with a poly K tail. Antibodies
recognizing eNOS, integrin b1, and caveolin-1 were
purchased from Abcam (Cambridge, Mass).
Antibodies recognizing VE-cadherin and E-cadherin
were purchased from Cell Signaling Technology
(Beverly, Mass) and Takara (Ohtsu, Japan),respectively. An antibody specific for b-catenin was
purchased from Becton Dickinson (Franklin Lakes,
NJ). Alexa Fluor 568–phalloidin and Alexa Fluor
488–cholera toxin subunit B (CTxB) were purchased
from Invitrogen. An inhibitor of cyclic adenosine
monophosphate (cAMP), Rp-cAMPS, and an
analogue of cGMP, 8-bromo-cGMP, were purchase
from Calbiochem (Darmstadt, Germany).
Deadhesion assay. A431 cells were plated at a sub-
confluent concentration in a 96-well plate and cultured
overnight. Next, 1 pmol/mL of recombinant protein
with an AP tag and/or chemically synthesized peptide
was added, and the plate was shaken for 30 minutes at
1,200 rpm on an OPM-103 microplate mixer (As One
Corporation, Osaka, Japan). Detached cells were
aspirated with a pipette and counted using a
hemocytometer. Recombinant activation peptide was
used as a negative control. The number of detached
cells in the negative control experiment was arbitrarily
set to 1. Results are expressed as the mean 6 standard
deviation (SD).
Immunohistochemistry. Cells were plated on
fibronectin-coated dishes. To examine the functions of
peptide 193-216, cells were treated with 1 pmol/mL
of chemically synthesized peptide 193-216 for
10 minutes. When staining with CTxB was necessary,
Alexa Fluor 488–CTxB was added to the medium
5 minutes before fixation. Cells were fixed in PBS
with 4% paraformaldehyde, permeabilized in PBS
with 0.1% Triton X-100, and incubated with primary
antibodies, followed by detection with Alexa Fluor
488– or Alexa Fluor 568–conjugated antirat, mouse,
or rabbit IgG (Invitrogen). When necessary, cells were
then stained with Alexa Fluor 568–phalloidin to detect
actin and Hoechst33342 to detect nuclei. Cells were
examined using an Axioskop 2 fluorescence
microscope (Carl Zeiss, Oberkochen, Germany) or a
TCS-SP5 confocal microscope (Leica, Wetzlar,
Germany). Images acquired using the Axioskop 2–
plus microscope at 100 3 final magnification were
analyzed using the Axiovision software package (Carl
Zeiss).
Cell shape analysis. Cells were plated subconfluently;
at 24 hours after plating, cells were treated with 1 pmol/
mL of peptide 193-216 for 30 minutes. Rp-cAMPS or 8-
bromo-cGMP was added to the medium 30 minutes
before fixation at various concentrations. The cells
were then fixed in PBS with 4% paraformaldehyde,
permeabilized in PBS with 0.1% Triton X-100 and
incubated with Alexa Fluor 568–phalloidin to detect
actin and Hoechst33342 to detect nuclei. Cells were
photographed under fluorescence microscopy. The
area of the dish covered with cells and number of
Translational Research
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(Digitalbeeing kid, Kanagawa, Japan). To evaluate the
thickness of lamellipodium-like protrusions,
photographs were acquired every micrometer using a
TCS-SP5 confocal microscope (Leica).
Electron microscopy. Cells were cultured on
fibronectin-coated cover-glasses for 16 hours and then
treated with 1 pmol/mL of peptide 193-216 for
30 minutes. Cells were then fixed in 4%
paraformaldehyde followed by 2.5% glutaraldehyde in
cacodylate buffer (pH 7.4), treated with 1%
cacodylate-buffered (0.1 M) OsO4, embedded in 1%
Epon812, and sectioned. Finally, ultra-thin sections
were stained with saturated uranyl acetate and lead
citrate and examined by electron microscopy.
Western blotting. HUVECs were cultured for 24 hours
in a 24-well dish and treated with 1 pmol/mL of
chemically synthesized activation peptide 193-216 for
various durations. Samples were harvested with
100 mL of sample buffer. Proteins in a sample (1/4)
were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to
a polyvinylidene fluoride membrane (ATTO, Tokyo,
Japan). The membrane was incubated with anti-eNOS
antibody (Abcam, Cambridge, UK) followed by a
horseradish peroxidase–conjugated secondary
antibody, and immunoreactive proteins were detected
using Western blot Ultra-sensitive HRP substrate
(Takara). Chemiluminescence was detected using
LumiCube (Liponix, Tokyo, Japan) and analyzed
using JustTLC software (Sweday, Lund, Sweden).
In vitro permeability assay. Experiments were con-
ducted using an In vitro Vascular Permeability Assay
kit (Chemicon, Billerica, Mass) according to the manu-
facturer’s protocol. Briefly, HUVECs were plated con-
fluently in the upper chambers and cultured with
100 ng/mL of IL-1b for 24 hours. The cells were then
cultured with various concentrations of chemically syn-
thesized peptide 193-216 or control peptide for 60 mi-
nutes. Fluorescein isothiocyanate-conjugated dextran
was added to the upper chambers, and after 5 minutes,
the medium from the lower chambers was harvested.
Florescence intensity was measured using a
microplate reader. The experiment was repeated 3
times. Results are expressed as the mean 6 SD.
Measurement of cGMP. Experiments were performed
using a cGMP Direct Immunoassay kit (Abcam).
Briefly, HUVECs were plated confluently in a 24-well
dish. The cells were then cultured with 10 pmol/mL
of chemically synthesized peptide 193-216 or control
peptide for various durations. Cell lysates were
prepared, and the amount of cGMP in the lysates was
determined according to the manufacturer’s protocol.The experiment was repeated 3 times. Results are
expressed as the mean 6 SD.
Mouse sepsis model. Animal experiments described
in this study were carried out in accordance with both
institutional and National Institutes of Health animal
care regulations. This study was approved by the animal
study committee of Nihon University (AP13M025).
Five-week-old male mice were purchased from CLEA
Japan (Tokyo, Japan). Mice were injected with LPS
(Wako, Tokyo, Japan) intravenously in the tail vein at
a dose of 100-mg/g body weight. After 3 hours, mice
were then injected intravenously in the tail vein with
chemically synthesized peptide 193-216 or control
peptide at 350-ng/g body weight, and 1 hour later,
mice were sacrificed by cervical dislocation and the
lungs immediately harvested. After the lungs were
weighed, 5-mm-thick frozen sections were prepared
and stained with hematoxylin and eosin.
Statistical analysis. Results are expressed as the
mean 6 SD. The significance of differences was evalu-
ated using Wilcoxon’s rank sum test. Statistical signifi-
cance was defined as P , 0.05.
RESULTS
Determination of the amino acid sequence essential for
the activity of the activation peptide of FIX. Kitano et al.24
established a deadhesion assay in which the functions of
the first EGF domain and the activation peptide of FIX
could be clearly quantified using A431 cells. Their
assay was used in the present study to determine the
FIX activation peptide amino acid sequence essential
for its activity (Supplemental Fig 1A). To characterize
the activity of the activation peptide, the effect of the
first EGF domain of FIX on cell adhesion was
examined. The first EGF domain of FIX-attenuated
cell adhesion to matrix, whereas full-length FIX
(amino acids 47-471) and a recombinant activation
peptide 193-236 suppressed this attenuation. Because
amino acid sequences of mammalian activation
peptides exhibit a high degree of homology at the N-
terminus, N-terminal peptides were chemically
synthesized (Supplemental Fig 1B). Chemically
synthesized peptide 193-216 also suppressed the
activity of the first EGF domain of FIX, but chemically
synthesized peptide 193-210 did not. Chemically
synthesized peptide 193-216 tended to be less effective
than peptide 193-236. However, from clinical
application perspective, short, chemically synthesized
peptides typically present a cost advantage. For further
study, we therefore used peptide 193-216.
Morphological changes induced by the activation
peptideof FIX. HUVECs were used to examine the effect
of the activation peptide on cell morphology. Fig 1A
Fig 1. Effects of chemically synthesized peptide 193-216 onHUVECs.A, The shape ofHUVECs treatedwith pep-
tide 193-216. Cells were stained with Alexa Fluor 568–phalloidin. Arrowhead indicates a lamellipodium in a con-
trol cell. Asterisks indicate lamellipodia in cells treatedwith peptide 193-216.Bar5 10mm.B, Relative intensity of
fluorescence associatedwith polymerized actin in control cells and cells treatedwith peptide 193-216 for 30min.C,
Thickness of lamellipodia in control cells and cells treatedwith peptide 193-216 for 30min.D, Cell adhesion area of
control cells and cells treated with peptide 193-216 for 30 min. Data are presented as the mean6 SD. **P, 0.01,
n5 220260. HUVECs, human umbilical vein endothelial cells; SD, standard deviation.
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the presence of peptide 193-216. Three minutes after
administration of the peptide, stress fibers
disappeared, and the intensity of fluorescence from
polymerized actin declined significantly (Fig 1A, B).
Another morphological change induced by peptide
193-216 was the formation of small lamellipodium-
like protrusions with actin bundles at their edges.
Some control cells exhibited similar lamellipodia, as
shown Fig 1A. The protrusions in the presence of the
peptide and those in control cells differed with respect
to thickness at the edge, as measured using confocal
microscopy. Most of the lamellipodia in control cells
were thicker than 5 mm, whereas most of the
lamellipodium-like protrusions in peptide-treated cells
were less thick than 5-mm thick (Fig 1C). The
extension of these protrusions in multiple directions
appeared to indicate spreading rather than migration.
Finally, 30 minutes after the administration of the
peptide, the cell-covered area increased by 16%
(Fig 1D). These data indicate that the FIX activation
peptide induces spreading in HUVECs.
Squamous cell carcinoma–derived A431 cells were
also used to examine the cell specificity of the morpho-
logical phenotype induced by the activation peptide.Control A431 cells adhered at several pointy protru-
sions, with intensive actin staining corresponding to
focal adhesions (Supplemental Fig 2A). By 30 minutes
after the administration of peptide 193-216, treated cells
assumed a square shape, with a few broad protrusions
exhibiting actin staining along the edges. The recombi-
nant activation peptide increased the average cell adhe-
sion area by 1.3 times compared with control cells
(Supplemental Fig 2B). The activity of the activation
peptidewith regard to cell spreading is thus not endothe-
lial cell specific.
To evaluate the effect of the activation peptide on
intercellular adhesion, subconfluently cultured HU-
VECs were used. The time course of intercellular adhe-
sion of cells treated with peptide 193-216 was examined
using immunohistochemistry with an anti–VE-cadherin
antibody and phalloidin (Fig 2A). The distribution of
VE-cadherin became fuzzy in appearance 30 minutes
after treatment with peptide 193-216 (Fig 2A, B). The
fuzzy intercellular adhesion was due to filopodia formed
between cells. The appearance of areas of
intercellular adhesion became more linear and sharper
after 60 minutes.
Another morphological change induced by peptide
193-216 was the appearance of widely spread
Fig 2. Effect of chemically synthesized peptide 193-216 on intercellular adhesion of HUVECs. Immunohisto-
chemistry of HUVECs stained with VE-cadherin–specific antibody (green), Alexa Fluor 568–phalloidin (red),
Translational Research
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(Fig 2A, C). To analyze these protrusions, HUVECs
were observed using confocal microscopy (Fig 2D).
At the level of 1.5 mm from the cover glass, VE-
cadherin was stained lineally and colocalized with poly-
merized actin, indicating that adherens junctions
involving VE-cadherin and actin were formed at this
level. At lower levels, VE-cadherin staining exhibited
a more ‘‘lacy’’ appearance, and the intercellular adhe-
sion interface as indicated by VE-cadherin extended
diagonally. Polymerized actin did not colocalize with
VE-cadherin at the lower levels. These results indicated
that adjacent cells overlapped at their interface and that
the architecture of cell adhesion was distinct from that
of a typical adherens junction.
It has been reported that intercellular adhesion be-
tween A431 cells is enhanced by the activation peptide.
To investigate whether the lamellipodium-like protru-
sions induced in endothelial cells by treatment with pep-
tide 193-216 are endothelial cell specific, A431 cells
were stained with antibodies against E-cadherin and
b-catenin (Supplemental Fig 3). Treatment with peptide
193-216 caused the areas of intercellular adhesion to
become more straight and continuous, but treatment
did not induce the formation of lamellipodium-like pro-
trusions as seen in HUVECs.
The endothelial cell–specific formation of
lamellipodium-like protrusions by treatment with pep-
tide 193-216 and their shape (Fig 2) reminded us of
the lateral border recycling compartment, an endothelial
cell–specific structure at sites of intercellular adhesion.
HUVECs were therefore stained with an antibody
specific for platelet endothelial cell adhesion molecule
(PECAM; a marker of LBRCs; Fig 3A) and an anti–b-
catenin antibody. In control cells, areas of intercellular
adhesion were stained with the anti–b-catenin antibody;
however, some areas of intercellular adhesion were not
stained with the anti-PECAM antibody. In contrast, in
HUVECs treated with peptide 193-216, b-catenin, and
PECAM were colocalized at sites of intercellular adhe-
sion. Digital magnification revealed that colocalization
of b-catenin and PECAMwas not homogeneous in con-
trol cells. The expression of b-catenin was linear, indi-
cating the presence of adherens junctions. However,
PECAM was not intensively expressed at adherens
junctions and was distributed widely (Fig 3B). In pep-and Hoechst33342 (blue). A, Intercellular adhesion of cells tr
B, High-magnification view of intercellular adhesion of cells t
C, Lamellipodium-like protrusions induced by treatment
Confocal microscopic observation of lamellipodium-like pro
peptide 193-216. Numbers to the left of the panels indicate d
indicate lamellipodium-like protrusions induced by treatm
Bars 5 10 mm. HUVECs, human umbilical vein endothelialtide 193-216–treated cells, a lace-like pattern of b-cat-
enin and PECAM colocalization was observed.
Colocalization of b-catenin and PECAM was subse-
quently analyzed by confocal microscopy. Vertical
cross-sectional views of HUVECs stained with anti-
bodies against b-catenin and PECAM are shown in
Fig 3C. In control cells, b-catenin was detected at
higher levels than PECAM, consistent with the location
of LBRCs along the basal side of adherens junctions. In
contrast, b-catenin and PECAMwere colocalized at the
sites of intercellular adhesion in the presence of peptide
193-216. To confirm that b-catenin was localized in ad-
herens junctions, cells were stained with antibodies
against VE-cadherin and b-catenin, both of which
were found to be colocalized in control cells and cells
treated with peptide 193-216 (Fig 3D).
For further study of intercellular adhesion in vitro,
scanning electron microscopy was used. In control cells
cultured for 16 hours, simple, short overlapping areas of
intercellular adhesion were observed (Fig 3E). In pep-
tide 193-216–treated cells, some areas of intercellular
adhesion exhibited an intricate configuration.
Our results suggest that cell spreading induced by
peptide 193-216 (Fig 1) effectively closes small gaps
between cells. In addition, the enhanced and intricate
configuration of intercellular adhesion induced by pep-
tide 193-216 (Figs 2 and 3) could increase the integrity
of the endothelial cell monolayer, thus decreasing its
permeability. To examine the effect of peptide 193-
216 on intercellular gaps, the number of gaps between
HUVECs was determined using fluorescence
microscopy (Fig 4A). Observation of HUVECs stained
with phalloidin and Hoechst33342 revealed small gaps
of several micrometers in diameter between cells, in
addition to small lamellipodium-like protrusions
several micrometers in width with actin bundles at their
edges along the intercellular interface. Treatment with
peptide 193-216 enlarged the protrusions along the
intercellular interface to tens of micrometers in width.
The number of gaps decreased by 66% in cells treated
with peptide 193-216 (Fig 4B). The observed deforma-
tion of the protrusions suggests that peptide 193-216
changes the configuration of the intercellular interface
to close intercellular gaps.
Effect of the activation peptide of FIX on endothelial cell
barrier function. To investigate the effect of theeated with chemically synthesized peptide 193-216.
reatedwith chemically synthesized peptide 193-216.
with chemically synthesized peptide 193-216. D,
trusions of cells treated with chemically synthesized
istance (mm) from the cover glass. Arrows in panels
ent with chemically synthesized peptide 193-216.
cells.
Fig 3. Intercellular adhesion of HUVECs treated with peptide 193-216. A, HUVECs stained with PECAM-
(green) and b-catenin–specific (red) antibodies and with Hoechst33342 (blue). Arrowheads indicate intercellular
adhesion without PECAM. Bar 5 20 mm. B, Digital magnifications of areas within rectangles in panels in A. C,
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Fig 4. Effect of peptide 193-216 on gaps in the endothelial monolayer. A, Gaps and protrusions between cells.
Cells were stained with Alexa Fluor 568–phalloidin (red) and Hoechst33342 (blue). Dotted lines indicate protru-
sions. Arrowhead indicates a gap between cells. B, Number of gaps between cells. Data are presented as the
mean6 SD. **P, 0.01, n5 50. C, HUVECs stained with VE-cadherin–specific antibody (green), Alexa Fluor
568–phalloidin (red), and Hoechst33342 (blue). Cells were treated with IL-1b or IL-1b and peptide 193-216. D,
Permeability of bovine aortic endothelial cells treated with IL-1b. Data are presented as the mean 6 SD.
**P , 0.01, n 5 6. Bars 5 10 mm. HUVECs, human umbilical vein endothelial cells; SD, standard deviation.
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immunohistochemistry and in vitro cell permeability as-
says were used. HUVECs were cultured in the presence
of IL-1b for 24 hours, and then the cells were incubated
with 10 pmol/mL of peptide 193-216 for 30minutes. IL-
1b inhibited intercellular adhesion, as evidenced by
staining with anti–VE-cadherin antibody and phalloi-
din, whereas peptide 193-216 suppressed this effect of
IL-1b (Fig 4C). In an in vitro model of permeability,
monolayers of endothelial cells were cultured in the
presence of IL-1b for 24 hours. The cells were then
incubated with various concentrations of the
synthesized peptide. Permeability was evaluated by
monitoring the passage of fluorescein isothiocyanate-
dextran through the cell monolayer (Fig 4D).Vertical confocal microscopic sectional views of HUVECs st
(red) antibodies. Bar5 1 mm. D, Vertical confocal microscop
herin– (green) and b-catenin–specific (red) antibodies. Dotted
tical sections. E, Transmission electron microscopic image
umbilical vein endothelial cells; PECAM, platelet endotheliaTreatment with IL-1b increased monolayer
permeability 6.5-fold. Peptide 193-216 suppressed the
IL-1b–induced increase in permeability dose
dependently, with suppression almost to the control
level observed with 10 pmol/mL of peptide 193-216.
We hypothesized that the activation peptide induces
the closure of small gaps between epithelial and endo-
thelial cell sheets via cell spreading. To investigate
whether the activation peptide promotes the healing of
small wounds in epithelial cell monolayers, the healing
process of a linear wound thewidth of a single cell made
using a razor blade was observed (Supplemental Fig 4).
In control experiments, cells migrated into the wound
within 30 minutes of injury. As a result of cell migra-
tion, new gaps were formed behind the migrating cells.ained with PECAM- (green) and b-catenin–specific
ic sectional views of HUVECs stained with VE-cad-
lines in left-side panels indicate positions of the ver-
s of HUVECs. Bar 5 200 nm. HUVECs, human
l cell adhesion molecule.
Fig 5. Effect of peptide 193-216 on eNOS expression in HUVECs.A,
Western blot analysis of eNOS expression. b-Actin served as a loading
control. B, HUVECs stained with eNOS- (green) and caveolin-1–spe-
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sulted in closure of the wound without the formation
of new gaps. These results suggest that the activation
peptide induces the closure of small gaps in epithelial
and endothelial cell sheets via promoting cell spreading.
Signaling mediated by the activation peptide of
FIX. The mechanisms of the activation peptide’s effects
were also investigated. Nitric oxide is known to mediate
hyper-permeability induced by humoral factors such as
VEGF and bradykinin. Western blotting (Fig 5A)
indicated a decrease in the level of eNOS expression
in HUVECs 30 minutes after administration of
peptide 193-216. Because cells responded to peptide
193-216 within several minutes (Fig 1A), the response
shown in Fig 5A is too slow. Thus, another
mechanism must explain the rapid response to peptide
193-216. The intracellular distribution of eNOS was
therefore investigated. The distribution of eNOS was
examined by immunocytochemical analysis at
10 minutes after peptide treatment (Fig 5B) using
caveolin-1, a marker of caveolae. Control cells
exhibited some clusters of caveolae at the cell edges,
particularly at protrusions. Treatment with the
activation peptide caused the cells to assume a
spheroidal shape, with smooth edges, with a 40%
decrease in the number of eNOS-containing clusters
of caveolae (Fig 5C). Colocalization of eNOS and
CTxB, a marker of lipid rafts, was also examined
(Supplemental Fig 5). CTxB colocalized with eNOS
at cell edges, as caveolin-1 did. Both eNOS and CTxB
disappeared from the membrane after treatment with
peptide 193-216. Because the decrease in eNOS
expression and change in the distribution of eNOS
protein suggested that peptide 193-216 suppresses
eNOS function, the amount of intracellular cGMP was
examined (Fig 5D). Peptide 193-216 treatment
significantly decreased the level of cGMP within
10 minutes. To investigate whether peptide 193-216
signaling is cGMP dependent, the effect of 8-bromo
cGMP was examined. Administration of 8-bromo
cGMP resulted in a dose-dependent suppression of
cell spreading induced by peptide 193-216 (Fig 5E).
Finally, the amount of intracellular cAMP was deter-
mined, because the phenotype induced by treatmentcific (red) antibodies and Hoechst33342 (blue). Arrows indicate accu-
mulation of eNOS and caveolin-1. Bars 5 20 mm. C, Number of
caveolin-1 clusters per cell; n 5 34. D, Effect of peptide 193-216 on
the amount of intracellular cGMP. E, Effect of 8-bromo-cGMP on
the adhesion area of cells treated with peptide 193-216. Data are pre-
sented as the mean 6 SD. **P , 0.01, *P , 0.05, n 5 6. HUVECs,
human umbilical vein endothelial cells; SD, standard deviation;
eNOS, endothelial nitric oxide synthase. (For interpretation of the ref-
erences to color in this figure legend, the reader is referred to the Web
version of this article.)
Fig 6. Effect of peptide 193-216 in sepsis model mice. Mice were
intravenously injected with peptide 193-216 (n 5 3) or LPS (n 5 7)
or LPS and peptide 193-216 (n 5 7). A, Ratio of lung weight to
body weight. Data are presented as the mean 6 SD. **P , 0.01. B,
Hematoxylin-eosin staining of lung tissue from a mouse injected
with LPS and peptide 193-216. Bar 5 200 mm. LPS, lipopolysaccha-
ride; SD, standard deviation.
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associated with an increase in cAMP. Treatment with
peptide 193-216 resulted in a slight decrease in the
intracellular cAMP level, rather than an increase
(Supplemental Fig 6A). To confirm that the signaling
pathway for spreading by cAMP was functioning in
our experimental system, the effects of a cAMP inhibi-
tor were examined (Supplemental Fig 6B, C). Rp-
cAMPS suppressed the increase in cell adhesion area
and decrease in polymerized actin induced by peptide
193-216.
Therapeutic effects of the activation peptide in a mouse
model of sepsis. Because the activation peptide was
shown to regulate eNOS expression and function and
suppress the permeability of the endothelial cell mono-
layer in an in vitro sepsis model (Fig 5D), it was
expected to demonstrate similar effects in an in vivo
sepsis model. First, normal mice were injected
intravenously with peptide 193-216 to examine the
safety of the peptide. No harmful effects associated
with the injection were noted on macroscopic
observation or by the wet lung/body weight ratio 1
hour after the injection (Fig 6A). Next, model mice
were generated by intravenous injection of LPS.
Peptide 193-216 was injected intravenously 3 hours
after LPS injection, and the lungs were harvested
60 minutes after peptide 193-216 administration. The
wet lung/body weight ratio significantly increased in
model mice, by 28%, but the injection of peptide 193-
216 significantly suppressed this increase.
Hematoxylin and eosin staining revealed that the lungspecimens from septic model mice had a thicker
interstitium, with cell infiltration, which was improved
by peptide 193-216 treatment (Fig 6B).DISCUSSION
This study showed that the activation peptide of FIX
induces cell spreading. Treatment with chemically syn-
thesized activation peptide decreased actin polymeriza-
tion within 3 minutes, induced the formation of
multidirectional thin and wide protrusions, and
increased the cell adhesion area. Peptide treatment
also changed the architecture of intercellular adhesion
sites. The shape of the cell interface became more com-
plex, and the distribution of adhesion molecules such as
VE-cadherin, b-catenin, and PECAM changed. These
effects of the activation peptide resulted in an increase
in the barrier function of endothelial cell monolayers
in vitro and regulated vascular permeability in vivo.
The signaling for cell spreading induced by the acti-
vation peptide involved a decrease in cGMP with
eNOS suppression. Treatment with the activation pep-
tide decreased the expression of eNOS protein and
altered its subcellular distribution. Intracellular cGMP
levels decreased rapidly after the administration of acti-
vation peptide. Addition of 8-bromo-cGMP abolished
the effect of the activation peptide on cell morphology,
indicating that a decrease in the level of cGMP is
essential for activation peptide signaling. The role of
the NO-cGMP pathway in endothelial barrier function
is controversial. Some reports indicate that cGMP pro-
tects the barrier function,27-29 but others do not.11,30-32
Surapisitchat and Beavo33 reviewed the relevant litera-
ture and reported that cGMP suppresses endothelial
permeability under physiological conditions and sup-
presses the barrier function under inflammatory condi-
tions. They proposed that cGMP activates PDE2,
which degrades cAMP under inflammatory conditions.
A decrease in cGMP could increase intracellular
cAMP levels, stimulating cell spreading, and preserving
the endothelial barrier function.34-37 In this study,
treatment with the activation peptide resulted in a
decrease rather than an increase in the intracellular
cAMP level. These results suggest that there are
cAMP-independent pathways in which a decrease in
cGMP level leads to cell spreading.
The suppression of caveolae clustering could be
involved in regulation of eNOS by the activation pep-
tide. In the present study, intracellular cGMP started
to decrease within 10 minutes after the treatment with
the activation peptide, and disappearance of eNOS
from the cell membrane was observed after 10 minutes,
with the loss of caveolae clusters. It has been reported
that eNOS is a caveolae protein and that internalization
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increasing activity.38,39 The inhibition of caveolae
clustering may play a negative role in NO generation
by inhibiting eNOS internalization. Sinha et al.40 re-
ported that the impairment of caveolae formation gener-
ates additional cell membrane in cells swollen under
hypotonic stress. Increased cell membrane area may
contribute to cell spreading induced by the activation
peptide.41
Cell spreading induced by the activation peptide is an
isotropic process involving multidirectional protrusions
and differs from spreading involving unidirectional la-
mellipodia for migration. Some studies have shown
that isotropic cell spreading in the early stage of cell
adhesion is a hydrodynamic process.42 The dynamics
of adhesion follow a universal power-law behavior
and are independent of the adhesion surface and the dis-
tribution of adhesion receptors. The process is largely
controlled by the membrane surface load and membrane
bending rigidity, which in turn is controlled by disrup-
tion of polymerized actin.43,44 In the present study,
treatment with activation peptide quickly reduced
actin polymerization and induced isotropic spreading.
The dismantling of the actin cytoskeleton could be
involved in cell spreading mediated by the activation
peptide.
Cell spreading appears to play an important role in
gap closure induced by the activation peptide.45,46
Many studies involving gap closure for the
maintenance of epithelial barrier functions have been
reported.47-50 Three mechanisms have been proposed.
The first mechanism involves gap closure by cell
migration with lamellipodium protrusions, controlled
by Rac1 GTPase.51,46 The second mechanism involves
purse-string closure by assembly and contraction of a
multicellular actomyosin belt lining the gap.52,53 This
process is controlled by RhoA, ROCK, and myosin
light-chain kinase. Anon et al.51 discussed a third mech-
anism for closure of gaps smaller than 20 mm. This
mechanism is independent of Rac1, ROCK, or myosin
light-chain kinase and could be based on cell spreading.
Treatment with peptide 193-216 induces the formation
of lamellipodial protrusions, suggesting that the first
mechanism based on cell migration with lamellipodial
protrusions could be the mechanism through which pep-
tide 193-216 acts. However, our experimental results
eliminate this mechanism. Cells formed multidirec-
tional protrusions in the presence of peptide 193-216
in the present study (Fig 1A). Generally, lamellipodia
used for migration are unidirectional. In addition, Ki-
tano et al. reported that the activation peptide of FIX
suppresses cell migration. Because treatment with pep-
tide 193-216 suppressed the formation of new gaps
behind migrating cells in the present study(Supplemental Fig 4), gap closure based on cell
spreading appears to be a likely mechanism of the acti-
vation peptide.
The distribution of PECAM plays roles in the remod-
eling of intercellular adhesion and the enhancement of
endothelial barrier function.54-57 Endothelial
permeability is regulated by 2 pathways, paracellular,
and transcellular. The paracellular pathway is
regulated by endothelial barrier–related genes, such as
those encoding adherens junction and tight junction
proteins. The activation peptide rearranged adherens
junction proteins and enhanced endothelial barrier
function. In addition, the activation peptide rearranged
PECAM at sites of intercellular adhesion. It has been
reported that PECAM is not an adherens junction
protein and is localized in LBRCs.58,59 However,
PECAM is essential for the formation of adherens
junctions. The colocalization of PECAM and adherens
junction components may be indicative of remodeling
of intercellular adhesion sites through their
interaction. PECAM is essential for leukocyte
diapedesis in LBRCs.60-62 How leukocytes can
migrate between endothelial cells and avoid
deleterious permeability changes remains an important
question. Interactions between PECAM and adherens
junction proteins may play critical roles in
maintaining the integrity of intercellular adhesion sites
and the regulation of endothelial cell layer permeability.
Possible physiological roles of the activation peptide
should also be discussed. Kitano et al. reported that
active FIX and recombinant proteins containing the first
EGF domain of FIX attenuate intercellular adhesion and
increase cell migration. In contrast, the inactive circula-
tory form of FIX and activation peptide act in an
opposing manner. In the present study, the activation
peptide opposed the action of the first EGF domain of
FIX (Supplemental Fig 1). These data indicate the pos-
sibility that the balance between active and inactive FIX
plays a significant role in the physiological function of
FIX. The functions of active FIX along with decreased
intercellular adhesion and increased cell migration are
reminiscent of VEGF-stimulated angiogenesis in
wound healing.63,64 However, it would seem unlikely
that suppression of angiogenesis by inactive FIX or
cleaved activation peptide is beneficial in wound
healing. A hypothesis to explain the function of
inactive FIX and activation peptide is that they
function in healthy tissues as opposed to wounds.
Inactive FIX could prevent healthy vessels from
endothelial hyper-permeability induced by active FIX
from injured tissue. In tissues in which blood flow is
preserved, inactive FIX supplied via the blood could
predominate over active FIX, contributing to the main-
tenance of endothelial barrier function. In contrast, in
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coagulation, active FIX could predominate but not
spread to healthy tissues due to the interruption of blood
flow. To prove this hypothesis, further study will be
necessary.
The activation peptide is a potential agent for use in
treating diseases in which vascular permeability is
increased. Intravenous injection with activation peptide
improves lung edema generated by endotoxin. This an-
imal disease model is considered to represent not only
sepsis but also systemic inflammatory response syn-
drome (SIRS), a condition involving systemic inflam-
mation, organ dysfunction, and organ failure.65,66 No
therapeutic methods for treating SIRS are currently
available. Barrier-protective endogenous molecules
such as thrombomodulin, S1P, and APC have been pro-
posed as agents for treating SIRS. Thrombomodulin
functions via cAMP.20 S1P and APC increase NO pro-
duction, and APC signaling is coordinately activated
with S1P.67,68 Our data indicate that the activation
peptide functions via a different signaling pathway
from those molecules. The activation peptide
mechanism is cAMP independent and requires a
decrease in cGMP. The activation peptide could thus
be used in a supplemental manner in the treatment of
pathologic conditions that are resistant to the above-
mentioned agents. With an eye toward clinical applica-
tions, the biological characteristics of the peptide,
including its circulating half-life, fate, and immunoge-
nicity, should be investigated.ACKNOWLEDGMENTS
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Volume 177 Mamiya et al 84.e1AppendixSupplemental Fig 1. Essential amino acid sequence of the activation peptide of mouse FIX.A, Effect of the acti-
vation peptide on cell adhesion. Cells were treated with recombinant protein of the first EGF motif (amino acids
97-130), which induced deadhesion of cells from the matrix. To evaluate the inhibitory effect of FIX fragments on
adhesion, the number of cells detached from the matrix was determined. Data are presented as the mean 6 SD.
**P, 0.01, n5 6. B, Comparison of mouse FIX activation peptide with that of other species. Amino acid residue
numbers are those for the mouse sequence. FIX, coagulation factor IX; SD, standard deviation.
Supplemental Fig 2. Effects of chemically synthesized peptide (amino acids 193-216) on A431 cells.A, Shape of
A431 cells treated with peptide 193-216. Cells were stained with Alexa Fluor 568–phalloidin. Dotted lines indi-
cate lamellipodia with a square shape. Bar indicates 20 mm.B, Cell adhesion areas of control cells and cells treated
with peptide 193-216 for 30 min. Data are presented as the mean6 SD. **P, 0.01, n5 210290. SD, standard
deviation.
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Supplemental Fig 3. Effect of peptide 193-216 on intercellular adhesion of A431 cells. A431 cells stained with
an antibodies specific for b-catenin (green) or E-cadherin (red) and with Hoechst33342 (blue). Bar indicates
10 mm.
Supplemental Fig 4. Closure of a narrow wound between A431 cells. For the linear wound healing assay, cells
were plated confluently and treated with 1 pmol/mL of chemically synthesized activation peptide (amino acids
193-216) for 30 min. A linear wound was then made in the monolayer with a razor blade. A431 cells were stained
with an anti–E-cadherin antibody (green), Alexa Fluor 568–phalloidin (red), and Hoechst33342 (blue). Arrows
indicate newly formed gaps behind cells facing a wound. Arrowheads indicate new intercellular adhesion after
injury. Bar indicates 10 mm.
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Supplemental Fig 5. Colocalization of eNOS and CTxB. HUVECs stained with an anti-eNOS antibody (green)
and Alexa Fluor 568–CTxB (red). Arrows indicate accumulation of eNOS and CTxB. Bar indicates 10 mm. eNOS,
endothelial nitric oxide synthase; HUVECs, human umbilical vein endothelial cells; CTxB, cholera toxin subunit
B.
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Supplemental Fig 6. The role of cAMP in peptide 193-216–treated
HUVECs.A, Amount of intracellular cAMP in the presence of peptide
193-216. B, Cell adhesion area in the presence of peptide 193-216 and
Rp-cAMPS. C, Fluorescence intensity of polymerized actin in the
presence of peptide 193-216 and Rp-cAMPS. Data are presented as
the mean 6 SD. *P , 0.05, **P , 0.01, n 5 6. cAMP, cyclic aden-
osine monophosphate; SD, standard deviation.
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